Xcout Intel
FIREBRICK PHARMA LIMITED competitors & alternatives
The 12 closest competitors and alternatives to FIREBRICK PHARMA LIMITED among pharmaceuticals, biotechnology & life sciences companies — ranked by similarity to what FIREBRICK PHARMA LIMITED actually does, not by market-cap band.
Subscribe to see FIREBRICK PHARMA LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About FIREBRICK PHARMA LIMITED
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.
FIREBRICK PHARMA LIMITED at a glance
FIREBRICK PHARMA LIMITED is a pharmaceuticals, biotechnology & life sciences company headquartered in Melbourne, Australia. It is publicly listed (FRE) with a market capitalisation of $4.8M. Xcout tracks 8 named people at FIREBRICK PHARMA LIMITED, including Simon Tucker (Chief Scientific Officer, BSc (Hons), PhD).
FIREBRICK PHARMA LIMITED leadership
- Simon TuckerChief Scientific Officer, BSc (Hons), PhD
- Stephen GoodallFounder, Director & COO, BAppSc, MAppSc, MBA, PhD
- Peter MolloyFounder & Executive Chairman, BSc, MBA, PhD
- Monique BaldwinHead of Regulatory Affairs, BSc (Hons), MBioethics, PhD
- Nilesh WadhwaBusiness Development Director
- Kam WatsonMarketing Administration Manager
2 more named people on record for FIREBRICK PHARMA LIMITED, with roles, board committees and tenure — see the full roster →
Top 12 FIREBRICK PHARMA LIMITED competitors
Ranked by semantic similarity — how close each company is to FIREBRICK PHARMA LIMITED by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals, biotechnology & life sciences company
Island Pharmaceuticals Ltd is an Australian antiviral drug development company based in Melbourne, Australia, focused on addressing infectious diseases.
Similar pharmaceuticals, biotechnology & life sciences company
AFT Pharmaceuticals Limited engages in the complete lifecycle of pharmaceutical products, from their initial development and licensing to their distribution and ultimate sale. The company's reach extends throughout New Zealand, Australia, Asia, and various other international markets. Its extensive product range encompasses treatments for allergies, cold and flu symptoms, ophthalmic conditions, first aid, pain management, digestive health, dermatological concerns, and medicated vitamin supplements. Established in 1997, AFT Pharmaceuticals has its corporate headquarters situated in Auckland, New Zealand.
Similar pharmaceuticals, biotechnology & life sciences company
Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.
Pharmaceuticals
Cloudbreak Pharma is an innovative biotechnology company headquartered in Irvine, California, with operations in Hong Kong. The company focuses on ophthalmic drug development, utilizing a robust research and development engine to create novel therapeutic solutions.
Similar pharmaceuticals, biotechnology & life sciences company
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Pharmaceuticals
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.
Similar pharmaceuticals, biotechnology & life sciences company
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
Similar pharmaceuticals, biotechnology & life sciences company
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures. Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries. Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas. The company was founded in 2012 and operates from its headquarters in Sydney, Australia.
Pharmaceuticals
Beroni Group Limited, established in 2014 and based in Sydney, Australia, is a global enterprise operating in China, Australia, the United States, and Japan. The company specializes in the creation and distribution of a diverse portfolio of health and wellness products. Its offerings span several key areas: Smoking Harm Reduction: This includes products like NicoBloc, designed to aid in smoking cessation. Environmental Quality: Beroni provides air purification systems, such as Fogibloc, and water filtration solutions under the Olansi brand. Health and Wellness: The company supplies a variety of health supplements and also markets cosmetic products, including V show rejuvenation liquids and various hyaluronic acid and avocado-based intensive treatment masks. Stem cell-derived cosmetic products are also part of its range. Diagnostic Tools: Beroni is active in the diagnostics field, offering detection kits for viruses like the SARS-CoV-2 IgG/IgM antibody kit for COVID-19, as well as the CII-ArboViroPlex rRT-PCR assay, which identifies arboviruses such as Zika, Dengue, Chikungunya, and West Nile. Beyond product sales, Beroni Group is heavily invested in research and development. Its R&D efforts focus on discovering and developing novel pharmaceutical drugs, conducting clinical trials, and advancing anti-cancer therapies. The company also provides services in gene detection and diagnosis, infectious disease diagnostics, and offers cell therapies for both cancer treatment and anti-aging applications. Furthermore, Beroni manages an e-commerce platform dedicated to pharmaceutical and healthcare products.
Similar pharmaceuticals, biotechnology & life sciences company
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei. The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers. Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile. Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of FIREBRICK PHARMA LIMITED and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for FIREBRICK PHARMA LIMITEDand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →